Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 8
2004 5
2005 11
2006 10
2007 15
2008 14
2009 17
2010 33
2011 56
2012 48
2013 41
2014 37
2015 54
2016 44
2017 27
2018 29
2019 27
2020 21
2021 16
2022 14
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

445 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Recommendations Made by Committee Members with and without Financial Conflict of Interest on Japanese Guideline of Treatment of Hyperuricemia and Gout, Third Edition.
Hisatome I, Hamada T, Mizuta E, Ohtahara A, Kuwabara M, Ogino K, Ninomiya H, Sato Y, Nakayama T, Yamanaka H. Hisatome I, et al. Among authors: yamanaka h. JMA J. 2023 Oct 16;6(4):523-526. doi: 10.31662/jmaj.2023-0067. Epub 2023 Sep 25. JMA J. 2023. PMID: 37941684 Free PMC article.
Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T, Nishikawa K, Yamada F, Morita A, Ohtsuki M, Suzuki Y, Watanabe M, Yamanaka H, Hibi T. Takeuchi T, et al. Among authors: yamanaka h. Drug Saf. 2023 Oct;46(10):991-1005. doi: 10.1007/s40264-023-01340-1. Epub 2023 Sep 12. Drug Saf. 2023. PMID: 37700154 Free PMC article.
Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: post-hoc subgroup analyses of the Japanese real-world observational "ORIGAMI" study.
Harigai M, Tanaka E, Inoue E, Tamura N, Misaki K, Azuma T, Hirata S, Hirano F, Taniguchi Y, Mitsuhashi M, Kondo M, Oribe M, Aoki K, Kadode M, Tsuritani K, Yamanaka H. Harigai M, et al. Among authors: yamanaka h. Mod Rheumatol. 2023 Aug 25:road082. doi: 10.1093/mr/road082. Online ahead of print. Mod Rheumatol. 2023. PMID: 37624029
Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI).
Misaki K, Tamura N, Azuma T, Shinoda K, Tanaka M, Fujiwara H, Tsuboi H, Kasama T, Yoshimi R, Hanyu T, Kusaka Y, Hirao M, Onishi M, Uchino A, Izumiyama T, Yang KS, Ogawa N, Matsui K, Kurasawa K, Kawaai S, Yasuoka H, Okumura N, Ueda Y, Tanaka E, Inoue E, Tsuritani K, Matsumoto S, Yamanaka H, Harigai M. Misaki K, et al. Among authors: yamanaka h. Mod Rheumatol. 2024 Feb 26;34(2):297-306. doi: 10.1093/mr/road045. Mod Rheumatol. 2024. PMID: 37233722
445 results